Clinical Trials
2 trialsNCT04580121 2024-06-03
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
Hoffmann-La Roche
Phase 1 Completed
NCT02923986 2020-05-28
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
Bio-Path Holdings, Inc.
Phase 1/2 Withdrawn